According to researchers at Columbia’s Alzheimer’s Research Center, scientists are pinpointing where the disease begins and how it progresses by studying cellular organelles called endosomes, which act as the brain’s Grand Central Station. While the exact triggers of Alzheimer’s have long eluded the medical community, current laboratory investigations are zeroing in on defective cellular transport systems that cause gridlock inside brain cells.
Tracking Cellular Gridlock in Alzheimer’s Disease
Alzheimer’s disease operates as a slowly progressive disorder, making it difficult for investigators to isolate the primary source once the brain is examined postmortem. According to Dr. Scott Small, director of Columbia’s Alzheimer’s Research Center, sifting through the debris of a fully damaged brain resembles searching for the origin of a raging house fire.
To overcome this challenge, Small and his team are examining endosomes, specialized organelles that move in and out of tens of millions of brain cells. Small compares these cellular pathways to a complex train track network. In this analogy, the endosome functions as Grand Central Station. When a specific problem train breaks down inside this microscopic transit hub, the nano shuttle collapses and creates complete traffic jams within the cell, according to Small’s findings.
Did you know? Inside the human brain, tens of millions of cells function as tiny transit hubs, utilizing moving organelles to help people think, move, and process emotions.
Developing Targeted Drugs and Animal Model Testing
Translating cellular discoveries into clinical treatments requires rigorous testing protocols. Dr. Yasir Qureshi, a researcher working alongside Small at Columbia, analyzes brain tissue from both mice and postmortem Alzheimer’s patients to evaluate parallel abnormalities.
“We can design questions based on the mouse studies, and then we can test them in those human brains, similar sections from similar areas that are representative,” Qureshi said, noting researchers check whether findings from animal subjects translate directly to human tissue.
Beyond merely replicating cellular damage in a lab setting, Qureshi’s team focuses on reversing the degenerative process, a concept he refers to as rescuing the cell. After expressing specific cellular factors in mouse models, researchers observed successful rescue of normal cellular processes. These promising outcomes point toward future academic studies and industry partnerships to develop potential pharmacological treatments, though none have entered human clinical trials yet. Small notes that his team is actively developing drugs designed to fix the broken cellular transport mechanisms.
Pro Tip: Researchers utilize comparative pathology—studying identical brain regions across both murine models and human donor tissue—to validate whether cellular rescue techniques can halt neurodegeneration.
Timeline for Breakthrough Therapies
Despite the complexity of neurodegenerative disorders, recent laboratory milestones leave Columbia researchers optimistic about near-future therapeutic breakthroughs. Small expresses strong confidence regarding the trajectory of their endosome-focused research.
“The home run will be hit, I’m sure of it,” Small said. “It may be two years, it may be five years, but we’re on the cusp.”
As academic laboratories transition from basic cellular observations to industry-backed drug development, the primary objective remains converting laboratory rescues into approved therapeutics for patients. For related health updates and local coverage, explore our Eyewitness News archives.
Frequently Asked Questions
Where does Alzheimer’s disease begin at a cellular level?
According to researchers at Columbia’s Alzheimer’s Research Center, the disease primarily begins with defects in endosomes, which act as cellular transit stations that manage internal transport within brain cells.
Are the new endosome-targeting drugs currently available to patients?
No. Dr. Scott Small confirms that while research teams are actively developing drugs to fix cellular traffic jams, these treatments have not yet entered human clinical trials.
How do scientists test Alzheimer’s treatments before human trials?
According to Dr. Yasir Qureshi, investigators conduct initial studies using mouse models and subsequently analyze similar brain sections from postmortem Alzheimer’s patients to verify whether findings translate to humans.
When do researchers expect a major breakthrough in Alzheimer’s treatment?
Dr. Scott Small states that researchers are on the cusp of a breakthrough, estimating a major therapeutic milestone could occur within two to five years as academic work transitions toward industry drug development.
What are your thoughts on these latest developments in Alzheimer’s research? Do you have a story idea or a news tip to share with our reporting team? Submit your feedback and tips to Eyewitness News to keep the conversation going.
Worth a look